Medicalgorithmics S.A.

Related Party Transaction • Dec 1, 2025

Report Content Subject:Medicalgorithmics S.A. expands cooperation with one of the largest U.S.IDTFs, increasing remuneration under the cooperation by over 50% inDecember 2025, to USD 450-500 thousand.

Date ofpreparation: 1 December 2025Legal basis:

Article 17(1) of MAR -inside information.Content of the report:

With referenceto Current Report No. 2/2025 of 24 January 2025 concerning theconclusion of a material agreement (the "Agreement") betweenMedicalgorithmics S.A. with its registered office in Warsaw (the"Company", the "Issuer") and a U.S.-based diagnostic center of the IDTFtype (the "Partner"), Current Report No. 18/2025 of 22 July 2025 inwhich the Company announced the commencement of the use of theDeepRhythmPlatform (DRP), and Current Report No. 28/2025 of 24 September2025 in which the Issuer indicated a significant increase in the volumeof examinations performed by the Partner using DRP, the Management Boardof the Company hereby informs that it received and approved on 1December 2025 for execution an additional order from the Partner for newservices not covered by the original Agreement, related to ECG dataanalysis. Thisorder is to be performed in December 2025 and includes an increasedscope of analyses compared to the level anticipated in the parties'previous arrangements.

As a result of the executionof the additional order, the expected remuneration of the Company fromthe Partner for December 2025 will increase significantly compared tothe Issuer's earlier assumptions. As indicated in Current Report No.28/2025, the Company estimated that the monthly remuneration foranalyzed sessions in Q4 2025 would exceed USD 300 thousand (approx. PLN1.1 million according to the NBP average exchange rate as of 23September 2025). In connection with the expanded scope of services, theIssuer currently assumes that remuneration from the Partner for December2025 will amount to between USD 450 thousand and USD 500 thousand, i.e.,approximately PLN 1.6-1.8 million according to the NBP average exchangerate as of 28 November 2025.

In the opinion of theManagement Board, the additional order and the expansion of the scope ofcooperation constitute an important step in implementing the Company'sstrategy presented in Current Report No. 16/2023 of 19 June 2023, aimedat significantly increasing the Company's revenues and profitability(thanks to its high operating leverage), as well as generating positivecash flows. The execution of the expanded scope of services will alsocontribute to strengthening business relations with the Partner, who isthe Company's main customer in the U.S. market.